Table 4.

Proportion of AEs according to patients’ sex and genotype

	TH			BZB
	TH treatment	TH AE	% of pts with AE	BZB treatment	BZB AE	% of pts with AE
male pts	41	25	61	23	6	26
female pts	26	12	46a	46	27	59b
ENG pts	17	17	100	10	2	20c
ACVRL1 pts	34	14	41	57	17	30d

Comparing males to females : ^ap=0.32, ^b<0.01. Comparing thalidomide to bevacizumab, ^cp<0.001, d=0.36